Abstract 1619: Personalized medicine: A CLIA-certified high-throughput drug screening platform for ovarian cancer
Hallie A. Swan(Precision for Medicine (United States)), Carla Grandori(Precision for Medicine (United States)), Roland M. Watt(Precision for Medicine (United States)), Rachele Rosati(Precision for Medicine (United States)), Franz X. Schaub(Precision for Medicine (United States)), Stephanie A. Murphy(Precision for Medicine (United States)), Robert L. Diaz, Shalini Pereira(Precision for Medicine (United States)), Reid Shaw(Precision for Medicine (United States)), Caroline Bridgwater(Precision for Medicine (United States)), Michael Churchill(Harvard University)
Cited by 5
Related Papers
The Myc/Max/Mad Network and the Transcriptional Control of Cell Behavior
|Annual Review of Cell and Developmental Biology|2000|1.3k
Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
|Cancer Discovery|2017|964
Direct activation of TERT transcription by c-MYC
|Nature Genetics|1999|903
Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion
|Proceedings of the National Academy of Sciences|2000|827
c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I
|Nature Cell Biology|2005|671